TGTX 8-K 2026-11-09

TG THERAPEUTICS, INC. (TGTX) 8-K dated 2026-11-09 — accession 0001628280-26-071870.

TG THERAPEUTICS, INC. (TGTX) is a biotechnology company listed on NASDAQ.

TGTX: TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported TGTX revenue for 2025-12-31 was $616.3M. Net income was $447.2M. Revenue was up 87.3% from 2024-12-31 to 2025-12-31. TGTX currently screens at market cap $7.88B and trailing P/E 23.1.

Not investment advice. The TGTX SEC hub lists recent forms. The stock page is the research view.